Provider review
Oria Meds Review: Careful Product Pages, and a Homepage Average No Trial Produced
Oria's semaglutide and tirzepatide pages are among the more careful in this market: each names the molecule, prints every plan price before you start, and warns that a trial average "describes a population, not what any one person should expect". The homepage card that links to the semaglutide page says something else: "Patients lose 15–20% of body weight on average." STEP 1, the trial Oria itself cites, averaged 14.9% over 68 weeks. And on that same product page, committing to three or six months costs more a month than paying month to month.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Oria MedsOf Oria Meds’s 2 dated product claims documented below, 0 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Its product pages name the molecule, price every plan and read the trials carefully; its homepage card promises an average weight loss above what the semaglutide trial produced.
Worth trusting if
- You want a pharmacy named with a street address, which PerfectRx is
- You want every plan length priced on a public page before you start
- You want a seller whose product pages explain side effects and trial caveats plainly
Be skeptical if
- You are expecting the 15–20% the homepage card advertises, because the semaglutide trial averaged less
- You are budgeting from the headline figure, which covers the first month only before the rate more than doubles
- You want to know which compounding rules govern your preparation, because the site never says
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Named
None found
Provenance
Products reviewed at Oria Meds
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide Weight Loss Program — $89 for the first month, then $199 a month. The product page lists three- and six-month plans at $209 a month, so committing longer costs more per month than paying monthly.
- Compounded Tirzepatide Weight Loss Program — $129 for the first month, then $369 a month, or $316 a month on three months and $299 on six.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not Oria Meds's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Oria Meds’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded Semaglutide Weight Loss ProgramSemaglutide · Compounded (503A)Claim reaches past the trials
“GLP-1 · Compounded GLP-1 medication · Starting at $89 first month, then $199/mo · GLP-1 receptor agonist · Patients lose 15–20% of body weight on average · One easy self-injection per week · Dosage adjusted by your doctor as you progress”
Read on the Oria Meds site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4mg, 68 weeks, alongside lifestyle intervention; mean weight reduction 14.9%. The trial used the branded product, and no randomized trial of a compounded preparation has been published.
The average on the card sits above the average the trial produced. STEP 1 gave semaglutide 2.4 mg for 68 weeks alongside structured diet and activity counseling, and the mean reduction was 14.9% — so a range of 15–20% "on average" starts at the trial's result and runs up from there, for a compounded preparation no randomized trial has tested. Oria's own semaglutide page gets this right: it cites STEP 1 without a headline figure, notes that participants had counseling throughout, and warns that a trial average describes a population rather than what any one person should expect. The card that sends readers to that page does not carry the same care.1
Compounded Tirzepatide Weight Loss ProgramTirzepatide · Compounded (503A)Claim reaches past the trials
“GLP-1 + GIP · Compounded dual GIP/GLP-1 medication · Starting at $129 first month, then $369/mo · Dual-action GIP + GLP-1 receptor agonist · Patients lose 20–25% of body weight on average · One easy self-injection per week · Dosage adjusted by your doctor as you progress”
Read on the Oria Meds site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide 5, 10 or 15 mg weekly for 72 weeks, alongside lifestyle intervention; mean weight reduction 15.0%, 19.5% and 20.9%. The trial used the branded product, and no randomized trial of a compounded preparation has been published.
The card's range begins where the trial's best result ended. In SURMOUNT-1 the highest dose, 15 mg for 72 weeks with lifestyle support, produced a mean reduction of 20.9%, and the lower doses produced 15.0% and 19.5%. A range of 20–25% "on average" therefore sits at or above the top-dose result, and is offered for a compounded preparation no randomized trial has tested, at whatever dose a patient reaches. Oria's own tirzepatide page is more careful than its card: it names SURMOUNT-1, says only that the higher doses beat placebo, and warns that comparing trial averages across drugs is not a head-to-head result.2
Dispensing chain
Who actually fills your prescription
- PerfectRx
Read the full account
Oria names its pharmacy — PerfectRx, at 5810 Long Prairie Rd, Flower Mound, Texas, with a telephone number — on its homepage and on each product page, where the footer reads "Dispensed by PerfectRx". That is more than most of this market discloses. What it leaves out is the compounding category: the product pages say the medication comes from "a licensed U.S. compounding pharmacy", and neither "503A" nor "503B" appears on the homepage, the product pages or the terms, so the site does not say which rules govern the preparation. The Terms describe "OriaMeds" as "a technology platform that facilitates access to telehealth services provided by independent licensed medical providers" and name no corporation or limited liability company; the footer gives a street address in Sheridan, Wyoming. No individual clinician is named.
Read on the Oria Meds site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. The product pages do carry the disclosure much of this market omits: that compounded medications are not FDA-approved and that "the FDA does not verify the safety, effectiveness, or quality of compounded drugs". They also list the common side effects and the serious risks, including the thyroid C-cell warning, rather than leaving them to the intake.
Read on the Oria Meds site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
The homepage badge row says "Licensed providers in all 50 states", and the footer adds "subject to provider availability and state-specific regulations". No per-state list is published.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The Terms describe OriaMeds as a technology platform that "does not practice medicine, does not employ physicians", and name no corporate form; the footer gives a Sheridan, Wyoming address. The named pharmacy partner is PerfectRx of Flower Mound, Texas.
Read on the Oria Meds site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names its pharmacy, PerfectRx, with a street address and telephone number, on every product page.
- Its semaglutide and tirzepatide pages each name the molecule and print the price of every plan length before you start.
- Its semaglutide page cites STEP 1 with the caveats that matter: participants had diet and activity counseling throughout, and a trial average describes a population, not a person.
Show 4 more
- It lists common side effects and serious risks, including the thyroid warning, on the product page.
- It says the price does not change when your dose does, and that you are charged only after a provider approves treatment.
- Its weight-loss copy is sympathetic and accurate about why weight regulation is hard, rather than blaming the reader.
- No FDA warning letter against Oria Meds or PerfectRx.
- Its homepage card says patients lose 15–20% of body weight on average; STEP 1 averaged 14.9% over 68 weeks with the branded drug.
- The tirzepatide card goes further still, at 20–25% on average; SURMOUNT-1's highest dose averaged 20.9% over 72 weeks.
- The semaglutide ladder is inverted — three- and six-month plans cost more per month than paying monthly.
Show 4 more
- The headline prices are first months only — after that, semaglutide is more than double and tirzepatide nearly triple.
- No compounding category is published; "503A" and "503B" appear nowhere on the product pages or the terms.
- No corporate form is published; the Terms name only the brand and call it a technology platform.
- No clinician is named.
Verdict
The bottom line
Read the product page, not the homepage card. The semaglutide page tells you what the drug is, what STEP 1 did and did not show, what every plan costs and what can go wrong — that is the honest version. The card above it promises a 15–20% average that the trial behind the drug did not reach. And if you buy, pay monthly: on semaglutide, the longer plans cost more per month.
Opens Oria Meds' website. A link is not a recommendation to take anything.
The product pages do the job
Oria has a page for each of its two drugs, and the semaglutide one covers most of what a buyer needs before signing up:
- The molecule, named in the title: Compounded Semaglutide Weight Loss Program.
- Every plan price: $89 for the first month, then $199 a month; three- and six-month plans at $209 a month.
- What it covers: clinical review, the medication, dose changes, care-team access and shipping — "The price does not change when your prescribed dose changes."
- The risks: the common gastrointestinal side effects, plus pancreatitis, gallbladder disease and the thyroid C-cell warning.
- The pharmacy: "Dispensed by PerfectRx", with a street address in Flower Mound, Texas.
Its evidence section is careful, too. It says STEP 1 ran 68 weeks against placebo 1, and then adds the caveats most sellers skip:
"Trial participants received structured diet and activity counselling throughout, so the medication was never studied as a standalone intervention. And individual response varies widely — a trial average describes a population, not what any one person should expect."
Full analysis — 4 more sectionsThe homepage card does not · The semaglutide ladder runs backwards · What is still not published · What sits beside the drug names
The homepage card does not
The card that links to that page reads:
GLP-1 · Compounded GLP-1 medication · Starting at $89 first month, then $199/mo · Patients lose 15–20% of body weight on average
STEP 1's mean was 14.9%, after 68 weeks on the branded drug with counseling throughout. A range of 15–20% "on average" starts at that result and runs up from it, for a compounded preparation that no randomized trial has tested.
The tirzepatide card beside it says 20–25%. In SURMOUNT-1, the highest dose of tirzepatide averaged 20.9% over 72 weeks, and the lower doses averaged 15.0% and 19.5%. 2 So the card's range starts at the best result in the trial and runs up from there. Oria's tirzepatide page, like its semaglutide page, says nothing of the kind: it names SURMOUNT-1, says the higher doses beat placebo, and warns against reading one trial's average as a head-to-head win.
It is the same company making both statements, one scroll apart. The product page says a trial average describes a population; the card turns a higher-than-trial average into a promise.
The semaglutide ladder runs backwards
| Plan | Per month |
|---|---|
| One month at a time | $199 |
| Three months | $209 |
| Six months | $209 |
Committing longer costs more. Tirzepatide goes the usual way — $369 a month, $316 on three months, $299 on six — which makes the semaglutide ladder stand out further.
What is still not published
The compounding category. The product pages say the medication comes from "a licensed U.S. compounding pharmacy". Neither "503A" nor "503B" appears on the homepage, the product pages or the terms, so the site does not tell you which set of rules governs the preparation.
Who runs it. The Terms describe OriaMeds as "a technology platform that facilitates access to telehealth services provided by independent licensed medical providers", which "does not practice medicine, does not employ physicians". No corporation or limited liability company is named; the footer gives a street address in Sheridan, Wyoming. No clinician is named anywhere.
What sits beside the drug names
"Doctor-led GLP-1 weight loss. You're not lazy. Your body isn't broken. Hunger hormones, cravings and a metabolism that fights back make weight loss genuinely harder."
That is a sympathetic paragraph and it is broadly accurate about weight regulation. On this site it now sits above cards that name both molecules and link to pages that explain them.
Questions
Frequently asked questions
Which drugs does Oria sell?
Compounded semaglutide and compounded tirzepatide. Each has its own page, linked from the homepage cards, naming the molecule and listing every plan price before you start.
Will I lose 15–20% of my body weight?
That is what the homepage card says patients lose on average, and it is more than the trial behind the drug found. STEP 1 averaged 14.9% over 68 weeks, on the branded product, with structured diet and activity counseling throughout. Oria's own semaglutide page puts it better: a trial average describes a population, not what any one person should expect.
Does Oria use a 503A or a 503B pharmacy?
The site does not say. The product pages describe "a licensed U.S. compounding pharmacy" and neither category appears on them or in the terms. It does name the pharmacy itself — PerfectRx, in Flower Mound, Texas — which is more than most sellers here disclose.
What will I pay?
Semaglutide is $89 for the first month, then $199 a month, or $209 a month on a three- or six-month plan — so the longer plans cost more. Tirzepatide is $129 for the first month, then $369 a month, falling to $316 on three months and $299 on six. The price covers the medication, dose changes, care-team access and shipping.
Who runs Oria Meds?
The site names no corporation or limited liability company. The Terms describe OriaMeds as a technology platform that connects patients with independent licensed providers, and the footer gives a street address in Sheridan, Wyoming. No clinician or medical director is named.
Glossary
Key terms
Show definitions
- GLP-1
- A class of drug, not a single medicine. Semaglutide and tirzepatide are both described this way and are different molecules with separate trials, effect sizes and safety profiles — tirzepatide additionally acts on a second receptor.
- Trial average
- The mean result across everyone in a trial arm. Individual results spread widely on either side of it, so an average is a description of a group, not a forecast for one person.
Compare
Others selling what Oria Meds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Oria Meds is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Oria Meds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 participants, 68 weeks, mean weight reduction 14.9%; the trial used branded semaglutide and no randomized trial of a compounded preparation has been published. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.